Technical Data
D1075-03D
DARPP32, phosphorylated (Thr34) (Dopamine- and cAMP-regulated Neuronal Phosphoprotein, DARPP-32, FLJ20940, Protein Phosphatase 1 Regulatory (Inhibitor) Subunit 1B, PPP1R1B)
Description:
DARPP-32 (dopamine and cyclic AMPregulated phosphoprotein, relative molecular mass 32,000) is a cytosolic protein highly enriched in medium-sized spiny neurons of the neostriatum (1). It is a bifunctional signaling molecule that controls serine/threonine kinase and serine/
threonine phosphatase activity (2). Dopamine stimulates phosphorylation of DARPP-32 through D1 receptors and activation of PKA. PKA phosphorylation of DARPP-32 at Thr34 converts it into an inhibitor of protein phosphatase 1 (1). DARPP-32 is converted into an inhibitor of PKA when phosphorylated at Thr75 by cyclin-dependent kinase 5 (CDK5) (2). Mice containing a targeted deletion of the DARPP-32 gene exhibit an altered biochemical, electrophysiological
and behavioral phenotype (3).

Applications:
Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 1:1000 Incubate membrane with diluted antibody in 5% BSA, 1X TBS, 0.1% Tween-20 at 4C with gentle shaking, overnight.
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG11C1022Purified
SizeStorageShippingSourceHost
100ul-20CBlue IceHumanRabbit
Concentration:
Not determined
Immunogen:
Synthetic phosphopeptide corresponding to residues surrounding Thr34 of human DARPP-32.
Purity:
Purified
Form
Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 100ug/ml BSA, 50% glycerol.
Specificity:
Recognizes endogenous levels of DARPP-32, phosphorylated at (Thr34). Species Crossreactivity: mouse, rat.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
(1) Nishi, A. et al. (1997) J. Neurosci. 17, 8147-8155. (2) Bibb, J.A. et al. (1999) Nature 402, 669-671.
(3) Fienberg, A.A. et al. (1998) Science 281, 838-842.